Embera NeuroTherapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Sudbury MA United States (2005)

Organization Overview

First Clinical Trial
2007
NCT00567814
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Embera NeuroTherapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

emb-01 (1 trial)

Drugs in Phase 2 Trials (2)

metyrapone (metopirone) (6 trials)

oxazepam (serax) (6 trials)

Drugs in Phase 1 Trials (2)

cocaine (Erythroxyline) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 2)

Tobacco Use Disorder (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5